文献速递临床试验与 GCP新药、器械与细胞基因治疗研发基础与转化研究

脑室内厌氧多巴胺治疗伴左旋多巴相关并发症的帕金森病:一项1/2期随机对照试验

Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trial.
PubMed 文献 · Nat Med · 2025-01-07

该研究采用腹部泵经皮下导管向第三脑室输注厌氧多巴胺(A-dopamine)。开放标签1期研究在12例患者中未观察到A-dopamine诱导的严重不良反应;随机对照开放标签交叉2期研究在9例患者中比较1个月A-dopamine与1个月优化口服抗帕金森病治疗,主要终点(腕表家庭活动记录仪盲法评估的超目标百分比)在A-dopamine期间显著降低(P=0.027),患者内中位差值为-10.4(Hedge g=-0.62,95%CI:-1.43,-0.08),家庭日记亦显著改善。

要点

  • 1期开放标签研究中12例患者未出现A-dopamine诱导的严重不良反应。
  • 2期交叉研究9例患者中,A-dopamine较优化口服治疗显著降低超目标百分比(P=0.027)。
  • 患者内中位差值为-10.4(Hedge g=-0.62,95%CI:-1.43,-0.08),家庭日记亦显著改善。

核心结论

  • 这些关于该新型设备辅助治疗可行性、安全性和效果的初步数据提示需通过大型随机双盲试验进行验证。

研究设计与样本

  • 开放标签1期研究在12例患者中评估A-dopamine的安全性。
  • 随机、对照、开放标签、交叉2期研究在9例患者中比较1个月A-dopamine与1个月优化口服抗帕金森病治疗。
  • A-dopamine经腹部泵连接植入第三脑室(靠近纹状体)的皮下导管给药。

主要发现

  • 1期开放标签研究显示12例患者中未出现A-dopamine诱导的严重不良反应。
  • 2期研究主要终点为腕表家庭活动记录仪盲法评估的超目标百分比(即出现运动障碍或运动迟缓的时间),A-dopamine较单用口服治疗显著降低(P=0.027),患者内中位差值为-10.4(Hedge g=-0.62,95%CI:-1.43,-0.08)。
  • 家庭日记亦显著改善。

局限性

  • 原文指出这些仅为关于可行性、安全性和效果的初步数据,提示需通过大型随机双盲试验进行验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Continuous compensation for cerebral dopamine deficiency represents an ideal treatment for Parkinson's disease. Dopamine does not cross the digestive and blood-brain barriers and is rapidly oxidized. The new concept is the intracerebroventricular administration of anaerobic dopamine (A-dopamine) using an abdominal pump connected to a subcutaneous catheter implanted in the third ventricle, near the striatum. An open-label phase 1 study showed no serious adverse reactions induced by A-dopamine in 12 patients. A randomized, controlled, open-label, crossover phase 2 study of 1 month of A-dopamine versus 1 month of optimized oral antiparkinsonian therapy was conducted in 9 patients. The primary endpoint, a blinded assessment of the percentage over target (that is, time with dyskinesia or bradykinesia), recorded by home actimetry using a wristwatch, was significantly reduced on A-dopamine compared with that on oral treatment alone (P = 0.027), with a median within-patient difference of -10.4 (Hedge g = -0.62 (95% confidence interval: -1.43, -0.08)). Home diaries were also significantly improved. These initial data on the feasibility, safety and effects of this new device-assisted therapy suggest validation by a large randomized double-blind trial. ClinicalTrials.gov registration: NCT04332276 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Moreau C, Odou P, Labreuche J, et al. Intracerebroventricular anaerobic dopamine in Parkinson's disease with L-dopa-related complications: a phase 1/2 randomized-controlled trial. Nat Med. 2025. PMID: 39775041. doi:10.1038/s41591-024-03428-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。